HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Rx-To-OTC Switch Of Low-Cost Smoking Cessation Drug Cystine Rejected By German Committee

Executive Summary

Low-cost smoking cessation alternaitve cystine and azelastine-fluticasone combination nasal spray Rx-to-OTC switch applications were rejected by Germany's independent Expert Committee on Prescription at its latest meeting. Olopatadine for ophthalmic use and oral bilastine at 10mg strength were, however, given the green light. 

You may also be interested in...

Why Did Germany Reject OTC Switch Of Low-Cost Smoking Cessation Drug Cytisine?

At its first meeting of 2023, Germany's switch committee voted against switching to OTC status low-cost smoking cessation drug cytisine. Complex treatment guidelines and concerns about side effects were among the considerations leading to this decision, the recently published minutes show.

German OTC Market News: Allergy, Pain And Sleep Launches From Sanofi, Teva And P&G

The latest German consumer healthcare launches: Sanofi adds bilastine antihistamine to Allegra range; Teva's Ratiopharm delivers paracetamol and ibuprofen combo thanks to Rx-to-OTC switch; and P&G livens up WICK ZzzQuil sleep aid gummies with tropical fruit flavour. 

Alternative Smoking Cessation Drug Cytisine On 2023 German Switch Committee Agenda

Low-cost alternative smoking cessation drug cytisine is under consideration by Germany's independent switch committee in January, alongside azelastine and fluticasone propionate in combination for intranasal use, olopatadine for ophthalmic use and bilastine (10mg) for oral use.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts